BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5. [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Bhandari R, Ogeyingbo OD, Kareem R, Gyawali M, Venkatesan N, Ahmed R, Botleroo RA, Elshaikh AO. Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review. Cureus 2021;13:e17729. [PMID: 34659943 DOI: 10.7759/cureus.17729] [Reference Citation Analysis]
2 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Manns MP. Issue Highlights. Clinical Gastroenterology and Hepatology 2019;17:2389-91. [DOI: 10.1016/j.cgh.2019.09.014] [Reference Citation Analysis]
4 Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048-1064. [PMID: 29869016 DOI: 10.1007/s00535-018-1480-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 18.8] [Reference Citation Analysis]
5 Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Saf 2019;42:617-32. [DOI: 10.1007/s40264-018-00783-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kucharzik T, Dignaß A, Siegmund B. Aktualisierung der Colitis ulcerosa Leitlinie 2020. Z Gastroenterol 2020;58:1209-32. [DOI: 10.1055/a-1296-3494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther 2020;51:852-60. [PMID: 32201971 DOI: 10.1111/apt.15680] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
8 Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 2020;20:205-13. [DOI: 10.1080/14712598.2020.1699529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
10 Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol 2022;15:175628482210807. [DOI: 10.1177/17562848221080793] [Reference Citation Analysis]
11 Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res 2021;19:71-82. [PMID: 32877600 DOI: 10.5217/ir.2019.09159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Cummings F, Gaya DR, Levison S, Subramanian S, Owen G, Rathmell A, Glen F, Demuth D, Meadowcroft S, Irving PM. A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study. Medicine (Baltimore) 2019;98:e14681. [PMID: 30817598 DOI: 10.1097/MD.0000000000014681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
14 Shi Y, He W, Zhong M, Yu M. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases. Genomics 2021;113:1988-98. [PMID: 33872704 DOI: 10.1016/j.ygeno.2021.04.011] [Reference Citation Analysis]
15 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Reference Citation Analysis]
16 Albshesh A, Ben-Horin S. Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF? Aliment Pharmacol Ther 2020;51:1198-9. [PMID: 32424929 DOI: 10.1111/apt.15712] [Reference Citation Analysis]
17 Laharie D. Towards therapeutic choices in ulcerative colitis. Lancet. 2017;390:98-99. [PMID: 28527707 DOI: 10.1016/s0140-6736(17)31263-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:76. [PMID: 32300596 DOI: 10.3389/fmed.2020.00076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol 2022;22:291. [PMID: 35676620 DOI: 10.1186/s12876-022-02347-1] [Reference Citation Analysis]
20 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
21 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
22 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Reference Citation Analysis]
23 Biancone L, Ardizzone S, Armuzzi A, Castiglione F, D'Incà R, Danese S, Daperno M, Gionchetti P, Rizzello F, Scribano ML, Vecchi M, Orlando A. Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opin Biol Ther 2020;20:1321-9. [PMID: 32662683 DOI: 10.1080/14712598.2020.1792882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 . UEG Week 2019 Oral Presentations. United European Gastroenterol J 2019;7:10-188. [PMID: 32213000 DOI: 10.1177/2050640619854670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
25 Bademci R, Erdoğan MA, Kara AY, Yiğittürk G, Erbaş O. Therapeutic effects of vitamin D on acetic acid-induced colitis in rats. Acta Cir Bras 2020;35:e202000404. [PMID: 32555936 DOI: 10.1590/s0102-865020200040000004] [Reference Citation Analysis]
26 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00856-2. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Reference Citation Analysis]
27 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
29 Forbes A. Immunosuppressants and immune modulators in luminal gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101759. [PMID: 34874843 DOI: 10.1016/j.bpg.2021.101759] [Reference Citation Analysis]
30 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hinojosa Del Val J, Barreiro-de Acosta M. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab. Gastroenterol Hepatol 2019;42:650-6. [PMID: 31635855 DOI: 10.1016/j.gastrohep.2019.08.007] [Reference Citation Analysis]
32 Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454-465. [PMID: 29205421 DOI: 10.1111/apt.14449] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
33 Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2018;48:839-51. [PMID: 30281832 DOI: 10.1111/apt.14930] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
34 Jossen J, Kiernan BD, Pittman N, Dubinsky MC. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2020;70:304-9. [DOI: 10.1097/mpg.0000000000002556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Miller C, Kwok H, Harrow P, Vega R, Seward E, Mehta S, Rahman F, Mccartney S, Parisi I, Lim SH, Sharma E, Samaan MA, Bancil A, Kok KB, Shalabi A, Johnston EL, Katarey D, Taherzadeh N, Murray C, Sharip MT, Carter MJ, Radhakrishnan ST, Peake S, Khakoo I, Wahed M, Povlsen S, Patel M, Dubois P, Finkel J, Onnie C, Bloom S. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101906] [Reference Citation Analysis]
36 Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:635-43. [PMID: 29370397 DOI: 10.1093/ecco-jcc/jjy004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
37 Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. United European Gastroenterol J 2020;8:1045-55. [PMID: 32772830 DOI: 10.1177/2050640620948802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
38 Atreya R, Reinisch W, Peyrin-biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Digestive and Liver Disease 2018;50:1019-29. [DOI: 10.1016/j.dld.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
39 Patel H, Latremouille-viau D, Burne R, Shi S, Adsul S. Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz022. [DOI: 10.1093/crocol/otz022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
40 Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:896-905. [PMID: 29430672 DOI: 10.1111/apt.14550] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 19.0] [Reference Citation Analysis]
41 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 26.0] [Reference Citation Analysis]
42 Lenti MV, Levison S, Eliadou E, Willert R, Kemp K, Carter A, Stansfield C, Assadsangabi A, Singh S, Crooks B, Tattersall S, Fairhurst F, Kenneth C, Subramanian S, Probert C, Storey D, Gregg B, Smith P, Liu E, Limdi JK, Johnston A, Hamlin PJ, Selinger CP. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Dig Liver Dis 2018;50:1299-304. [PMID: 30077465 DOI: 10.1016/j.dld.2018.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
43 Truffi M, Sevieri M, Morelli L, Monieri M, Mazzucchelli S, Sorrentino L, Allevi R, Bonizzi A, Zerbi P, Marchini B, Longhi E, Sampietro GM, Colombo F, Prosperi D, Colombo M, Corsi F. Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease. Int J Nanomedicine 2020;15:8537-52. [PMID: 33173291 DOI: 10.2147/IJN.S264513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, Tung SY, Chung CS, Su MY, Chiu CT. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study. J Formos Med Assoc 2021:S0929-6646(21)00532-5. [PMID: 34924273 DOI: 10.1016/j.jfma.2021.11.012] [Reference Citation Analysis]
45 Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis 2019;4:70-80. [PMID: 31093599 DOI: 10.1177/2475530318810851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
46 Liefferinckx C, Minsart C, Cremer A, Amininejad L, Tafciu V, Quertinmont E, Tops S, Devière J, Gils A, van Gossum A, Franchimont D. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol 2019;31:478-85. [PMID: 30672828 DOI: 10.1097/MEG.0000000000001356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
47 Chen J, Girard M, Wang S, Kisfalvi K, Lirio R. Using supervised machine learning approach to predict treatment outcomes of vedolizumab in ulcerative colitis patients. J Biopharm Stat 2021;:1-16. [PMID: 34882518 DOI: 10.1080/10543406.2021.2009500] [Reference Citation Analysis]
48 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
49 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
50 Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-biroulet L. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therap Adv Gastroenterol 2022;15:175628482210908. [DOI: 10.1177/17562848221090834] [Reference Citation Analysis]
51 Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf) 2020;8:306-11. [PMID: 32843978 DOI: 10.1093/gastro/goz041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
53 Schäffler H, Huth A, Lamprecht G, Anders O. Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A. Case Rep Gastroenterol 2017;11:774-9. [PMID: 29606934 DOI: 10.1159/000485372] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00331-9] [Reference Citation Analysis]
55 Ikeuchi A, Kakiuchi T, Ibi A, Matsuo M. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan. Clin J Gastroenterol 2021;14:146-51. [PMID: 33040281 DOI: 10.1007/s12328-020-01260-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
57 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis 2019;25:270-82. [PMID: 30165490 DOI: 10.1093/ibd/izy269] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
58 Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00298-3. [PMID: 34798039 DOI: 10.1016/S2468-1253(21)00298-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
59 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. J Crohns Colitis. 2018;12:245-257. [PMID: 29077833 DOI: 10.1093/ecco-jcc/jjx143] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 18.5] [Reference Citation Analysis]
61 White JR, Din S, Ingram RJM, Foley S, Alam MA, Robinson R, Francis R, Tucker E, Jalal M, Elphick D, Atallah E, Norman A, Amin M, Sajjad A, Heggs N, Meadowcroft S, Moran GW. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology 2020;55:907-16. [DOI: 10.1080/00365521.2020.1790647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880 [PMID: 29740202 DOI: 10.3748/wjg.v24.i17.1868] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
63 Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol 2021;14:17562848211023386. [PMID: 34276808 DOI: 10.1177/17562848211023386] [Reference Citation Analysis]
64 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
65 Naessens D, Cameron C, Hoaglin DC. Network Meta-analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects From Induction and Bias of the Results. Clin Gastroenterol Hepatol 2021;19:2219-21. [PMID: 33065309 DOI: 10.1016/j.cgh.2020.10.016] [Reference Citation Analysis]
66 Hanauer SB. Issue Highlights. Clinical Gastroenterology and Hepatology 2017;15:161-3. [DOI: 10.1016/j.cgh.2016.12.001] [Reference Citation Analysis]
67 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
68 Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.Inflamm Bowel Dis. 2019;25:1805-1812. [PMID: 30931477 DOI: 10.1093/ibd/izz057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
69 Bilsborough J, Fiorino MF, Henkle BW. Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis. Expert Opin Drug Discov 2021;16:567-77. [PMID: 33245673 DOI: 10.1080/17460441.2021.1851185] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
71 Dalal RS, McClure EL, Marcus J, Allegretti JR. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. Dig Dis Sci 2022. [PMID: 35415826 DOI: 10.1007/s10620-022-07472-1] [Reference Citation Analysis]
72 Nguyen VQ, Eden K, Morrison HA, Sammons MB, Knight KK, Sorrentino S, Brock RM, Grider DJ, Allen IC, Sorrentino D. Noncanonical NF-κB Signaling Upregulation in Inflammatory Bowel Disease Patients is Associated With Loss of Response to Anti-TNF Agents. Front Pharmacol 2021;12:655887. [PMID: 34177575 DOI: 10.3389/fphar.2021.655887] [Reference Citation Analysis]
73 Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center. J Dig Dis 2019;20:235-42. [PMID: 30927309 DOI: 10.1111/1751-2980.12748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
74 Seo GS, Lee SH. [Emerging Therapies: What Are Promising in the Near Future?]. Korean J Gastroenterol 2018;71:81-8. [PMID: 29471605 DOI: 10.4166/kjg.2018.71.2.81] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Iborra M, Beltrán B, Maroto N, Navarro-cortés P, Boscá-watts M, Ferrer-bradley I, García-morales N, Sáez-gonzález E, Hinojosa J, Mínguez M, Nos P. Vedolizumab, una opción en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biológicos. Gastroenterología y Hepatología 2018;41:535-43. [DOI: 10.1016/j.gastrohep.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
77 Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Lenti MV, Mengoli C, Vernero M, Aronico N, Conti L, Borrelli de Andreis F, Cococcia S, Di Sabatino A. Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease. Front Immunol 2020;11:485. [PMID: 32269571 DOI: 10.3389/fimmu.2020.00485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn's disease. Lancet Gastroenterol Hepatol 2020;5:80-92. [PMID: 31818474 DOI: 10.1016/S2468-1253(19)30340-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
80 Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00222-6. [PMID: 33684552 DOI: 10.1016/j.cgh.2021.02.043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
81 Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ. Vedolizumab and Anti-TNFα Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis 2021:jjab058. [PMID: 33786600 DOI: 10.1093/ecco-jcc/jjab058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
82 Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand J Gastroenterol 2018;53:158-67. [PMID: 29258369 DOI: 10.1080/00365521.2017.1416160] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
83 Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflammatory Bowel Diseases 2018;24:286-95. [DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
84 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Zingone F, Barberio B, Compostella F, Girardin G, D'Incà R, Marinelli C, Marsilio I, Lorenzon G, Savarino EV. Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. Therap Adv Gastroenterol 2020;13:1756284820936536. [PMID: 32695231 DOI: 10.1177/1756284820936536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
86 Felice C, Pugliese D, Guidi L. TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine. EBioMedicine 2019;41:40-1. [PMID: 30808577 DOI: 10.1016/j.ebiom.2019.02.045] [Reference Citation Analysis]
87 Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11:e0165435. [PMID: 27776175 DOI: 10.1371/journal.pone.0165435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 9.7] [Reference Citation Analysis]
88 Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci 2018;63:825-33. [PMID: 29484571 DOI: 10.1007/s10620-018-4971-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
89 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
90 Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis 2017;11:1230-7. [PMID: 28605483 DOI: 10.1093/ecco-jcc/jjx082] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
91 Jin QW, Wang XD. Progress in research of vedolizumab in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 248-255 [DOI: 10.11569/wcjd.v29.i5.248] [Reference Citation Analysis]
92 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 45.0] [Reference Citation Analysis]
93 Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis 2018;24:2442-51. [PMID: 29788318 DOI: 10.1093/ibd/izy155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
94 Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113:1345. [PMID: 29946178 DOI: 10.1038/s41395-018-0162-0] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 16.5] [Reference Citation Analysis]
95 Stewart MJ, Bessissow T, Gregor J, Hazel M, In TSH, Karra K, Dajnowiec D, Williamson M, Sattin B. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Adv Ther 2021;38:4115-29. [PMID: 34159558 DOI: 10.1007/s12325-021-01818-3] [Reference Citation Analysis]
96 Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. J Crohns Colitis 2020;14:1190-201. [PMID: 32100016 DOI: 10.1093/ecco-jcc/jjaa035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
97 . Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). Z Gastroenterol 2022;60:1047-50. [DOI: 10.1055/a-1851-7777] [Reference Citation Analysis]
98 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Reference Citation Analysis]
99 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. World J Gastroenterol 2022; 28(26): 3092-3100 [DOI: 10.3748/wjg.v28.i26.3092] [Reference Citation Analysis]
101 Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-8. [PMID: 34224299 DOI: 10.1080/00365521.2021.1946588] [Reference Citation Analysis]
102 Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath MF, Kulisek N, Paulissen J, Su C, Ponce de Leon D, Regueiro M. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2022:izac061. [PMID: 35380664 DOI: 10.1093/ibd/izac061] [Reference Citation Analysis]
103 Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019; 17: 130-138. e7. [PMID: 29857145 DOI: 10.1016/j.cgh.2018.05.026] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
104 Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0212989. [PMID: 30807613 DOI: 10.1371/journal.pone.0212989] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]